Several @entity4149 kinase inhibitors (TKIs) are approved for @entity1860 ( @entity1860 ) therapy. We evaluated the long-term cost-effectiveness of seven sequential therapy regimens for @entity1860 in Austria. A cost-effectiveness analysis was performed using a state-transition Markov model. As model parameters, we used published trial data, clinical, epidemiological and economic data from the Austrian @entity1860 registry and national databases. We performed a cohort simulation over a life-long time-horizon from a societal perspective. @entity10542 without second-line TKI yielded an incremental cost-utility ratio of 121,400    /quality-adjusted life year (QALY) compared to @entity2213 without second-line TKI after @entity2213 failure. @entity2213 followed by @entity10542 after failure resulted in 131,100    /QALY compared to @entity10542 without second-line TKI. @entity10542 followed by @entity8947 yielded 152,400    /QALY compared to @entity2213 followed by @entity10542 after failure. Remaining strategies were dominated. The sequential application of TKIs is standard-of-care, and thus, our analysis points toward @entity2213 followed by @entity10542 as the most cost-effective strategy.

Cost-effectiveness of the sequential application of @entity4149 kinase inhibitors for the treatment of XXXX .

@entity8947 :: ('MESH:C488369', 'Chemical') :: ['dasatinib'] @entity4149 :: ('D014443', 'Chemical') :: ['tyrosine'] @entity1860 :: ('MESH:D015464', 'Disease') :: ['CML', 'chronic myeloid leukemia'] @entity10542 :: ('MESH:C498826', 'Chemical') :: ['Nilotinib', 'nilotinib'] @entity2213 :: ('MESH:C097613', 'Chemical') :: ['imatinib', 'Imatinib']
@entity1860 :: (MESH:D015464,Disease) :: ['chronic myeloid leukemia']
